View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
September 29, 2010

Microfluidic Device Developed to Identify Aggressive Breast Cancers

Researchers at the University of South Australia have developed a disposable device that can identify aggressive breast cancers. Patients with aggressive breast cancers have abnormal levels of protein HER2 in their blood. Model and validation studies conducted by the researchers

By cms admin

Researchers at the University of South Australia have developed a disposable device that can identify aggressive breast cancers.

Patients with aggressive breast cancers have abnormal levels of protein HER2 in their blood.

Model and validation studies conducted by the researchers showed that the microfluidic device is able to capture HER2 positive cells from blood with 80% accuracy.

Study researcher Benjamin Thierry said that microfluidic devices offer a unique opportunity to efficiently isolate circulating tumour cells from patient’s blood.

“We hope that our device will provide a fast, reliable and affordable methodology to establish HER2 status for breast cancer patients presenting metastases, thereby enabling the selection of more potent therapy based on trastuzumab,” Thierry added.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management